RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Question"The PK profiles of TH1902 and free docetaxel will be evaluated for all patients in Parts 1 and 2. Once the MTD has been reached in Part 1, patients with TNBC, gynecological cancer (epithelial ovarian or endometrial cancer), colorectal cancer and pancreatic cancer (10 patients per cancer type) will be enrolled in Part 2 and treated at the MTD or RP2D to further assess the safety and tolerability of TH1902. The preliminary anti-tumor activity of TH1902 will be evaluated for all patients as per the response evaluation criteria in solid tumors (RECIST 1.1; Eisenhauer, 2009)."
I think the PoC for Phase1 as per trial description will be at the end of part2 as their final assessment re safety and tolerability will be at that stage so the payment in common shares should be at the end of phase1.